These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 553398)

  • 1. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
    Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
    Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
    [No Abstract]   [Full Text] [Related]  

  • 2. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 3. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Painful dystonic spasms in Parkinson's disease.
    Ilson J; Fahn S; Côté L
    Adv Neurol; 1984; 40():395-8. PubMed ID: 6695618
    [No Abstract]   [Full Text] [Related]  

  • 5. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
    Klawans HL; Tanner CM; Glatt S; Goetz CG
    Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists.
    Goldstein M; Engel J; Lieberman A; Regev I; Bystritsky A; Mino S
    J Neural Transm Suppl; 1983; 18():257-63. PubMed ID: 6135744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide mesylate: new therapy for Parkinson disease.
    Tanner CM; Klawans HL
    Ann Intern Med; 1982 Apr; 96(4):522-3. PubMed ID: 7065569
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: new drugs help but no cure on the horizon.
    González ER
    JAMA; 1981 Jul; 246(1):11-2. PubMed ID: 7241717
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease.
    Kleinberg DL; Lieberman A; Todd J; Greising J; Neophytides A; Kupersmith M
    J Clin Endocrinol Metab; 1980 Jul; 51(1):152-4. PubMed ID: 6769937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 20. Pergolide in Parkinson's disease.
    Goetz CG; Tanner CM; Glantz R; Klawans HL
    Arch Neurol; 1983 Dec; 40(13):785-7. PubMed ID: 6639407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.